Human herpesvirus 6 encephalitis is a serious brain infection that occurs when a common childhood virus reactivates, particularly in people with weakened immune systems, potentially causing lasting neurological damage despite treatment.
Human herpesvirus 6, often shortened to HHV-6, belongs to a family of viruses that most of us carry without even knowing it. This virus exists in two distinct forms—type A and type B—and while type B infects more than 90 percent of children by the age of three, type A remains less understood and typically affects adults, often without causing noticeable symptoms. The virus spreads worldwide, usually passing from mother to infant, and then settles quietly into blood cells, salivary glands, and even the brain, where it remains dormant for years or even a lifetime.[1]
When the immune system weakens, however, this sleeping virus can wake up and cause serious problems. The reactivation of HHV-6 can lead to encephalitis, which means inflammation of the brain. This condition poses the greatest threat to people whose immune defenses have been compromised by conditions such as HIV/AIDS, cancer treatments like chemotherapy, organ or stem cell transplants, or medications that intentionally lower immunity to prevent organ rejection. In these vulnerable individuals, the virus can attack the brain and cause devastating complications.[1]
Epidemiology
HHV-6 infection is remarkably common throughout the world. Studies have consistently shown that infection rates approach 100 percent in human populations, meaning nearly everyone has been exposed to this virus at some point in their lives. The primary infection with HHV-6B typically occurs during the first two years of life, and seroprevalence rates—meaning the percentage of people who show antibodies to the virus—surpass 95 percent in most research studies. This makes HHV-6 one of the most widespread viral infections affecting humans.[4]
Infection is nearly universal by age two years, with most children acquiring the virus during infancy or early childhood. The virus was first identified in 1986 from blood samples of adults with lymphoproliferative diseases and AIDS, though at that time researchers did not yet understand how common it would prove to be. Initially called human B-lymphotropic virus, it was later renamed human herpesvirus 6 as the sixth herpesvirus to be isolated from humans.[2]
While primary infection with HHV-6B is extremely common in young children, HHV-6 encephalitis as a disease entity occurs much more rarely and almost exclusively in people with compromised immune systems. The condition has been studied most thoroughly in recipients of hematopoietic stem cell transplants and solid organ transplants. Among stem cell transplant recipients, HHV-6 reactivation occurs in 35 to 46 percent of all cases, with rates climbing as high as 90 percent in those who receive umbilical cord blood transplants. The typical time for reactivation ranges from 20 to 29 days after transplantation.[12]
HHV-6 encephalitis was first described as a clinical entity in 1994, and since then it has been recognized as the most feared complication of HHV-6 disease, particularly in transplant recipients. The demographic pattern shows that while the initial childhood infection affects nearly everyone regardless of gender or ethnicity, the serious complication of encephalitis disproportionately affects those whose immune systems cannot keep the virus in check.[4]
Causes
The root cause of HHV-6 encephalitis lies in the unique life cycle of this herpesvirus. Like other members of the herpes family, HHV-6 establishes what doctors call a latent infection after the initial illness resolves. This means the virus never truly leaves the body; instead, it hides quietly inside cells, particularly in lymphocytes (a type of white blood cell), monocytes, and various other cells throughout the body including those in the brain. During this dormant phase, the virus causes no symptoms and creates no problems.[3]
The trouble begins when something disrupts the delicate balance between the virus and the immune system. When immune defenses weaken significantly, the dormant virus can reactivate and begin multiplying again. This reactivation sets the stage for brain inflammation. The virus has a particular tendency to affect the central nervous system, and when it does, it can cause the serious condition known as encephalitis.[1]
Several specific circumstances can trigger this reactivation. HIV/AIDS profoundly weakens the immune system by attacking the very cells that coordinate immune responses. Cancer treatments, particularly chemotherapy, deliberately suppress immune function to kill cancer cells but leave the body vulnerable to opportunistic infections. People who receive organ or stem cell transplants must take powerful immunosuppressive medications to prevent their bodies from rejecting the new organ, and these medications create an environment where HHV-6 can flourish again. Any medication or disease that significantly lowers immunity can potentially allow the virus to reactivate and cause disease.[2]
Risk Factors
Certain groups of people face much higher risks of developing HHV-6 encephalitis compared to the general population. The most significant risk factor is profound immunosuppression from any cause. Transplant recipients represent one of the highest-risk groups, particularly those who have received hematopoietic stem cell transplants for blood cancers or bone marrow disorders. These patients undergo intensive conditioning regimens that essentially wipe out their existing immune system before receiving new stem cells, creating a window of extreme vulnerability during which HHV-6 can reactivate and attack the brain.[2]
Among transplant recipients, those who receive umbilical cord blood transplants face particularly elevated risks, with reactivation rates reaching as high as 90 percent. Solid organ transplant recipients also experience increased risk, though generally to a lesser degree than stem cell transplant patients. The immunosuppressive medications these patients must take indefinitely to prevent organ rejection create ongoing risk for viral reactivation.[12]
People living with advanced HIV infection or AIDS face heightened risk because the virus that causes AIDS specifically targets and destroys the immune cells that would normally keep HHV-6 in check. Patients with hematologic malignancies—cancers of the blood and bone marrow such as leukemia and lymphoma—are also at increased risk both because of their underlying disease and because of the intensive chemotherapy used to treat these cancers.[2]
The timing of risk matters as well. For stem cell transplant recipients, the period of greatest vulnerability typically occurs between two and four weeks after transplantation, when immune reconstitution is just beginning but remains incomplete. During this window, the combination of profound immunosuppression and potential viral reactivation creates the perfect conditions for HHV-6 encephalitis to develop.[12]
Interestingly, a small percentage of the population—less than 1 percent—are born with HHV-6 integrated directly into their chromosomes, a condition called chromosomally integrated HHV-6. While the implications of this unusual situation are not fully understood, it represents a unique form of vertical transmission from parent to child and may carry its own distinct risks for reactivation and disease.[4]
Symptoms
The symptoms of HHV-6 encephalitis differ dramatically depending on whether the patient is a child with a normal immune system or an immunocompromised adult. In most children who experience primary HHV-6B infection, the illness manifests as a common childhood condition called roseola infantum or exanthem subitum, also known as sixth disease. These young patients typically develop a high fever followed by a characteristic rash. Some children may also experience seizures related to the fever, and occasionally, though rarely, some develop encephalitis that shows up as irritability and behavioral changes. Fortunately, most of these symptoms resolve on their own within five to seven days without any lasting problems.[1]
The picture looks quite different in adults with weakened immune systems who develop HHV-6 encephalitis. These patients typically present with fever as an initial symptom, but what follows can be far more serious. Adults may show symptoms of graft rejection if they have received a transplant, along with dangerously low sodium levels in their blood. The neurological symptoms can be particularly concerning and include confusion, forgetfulness, and behavioral changes that may seem out of character for the patient. Seizures can occur and may be severe. Some patients experience memory problems or even amnesia.[1]
In transplant recipients specifically, doctors may observe signs of cognitive dysfunction, which means problems with thinking clearly or processing information. Some patients develop what is called limbic encephalitis, where inflammation affects the limbic system of the brain, leading to memory problems, confusion, and changes in behavior or personality. Other patients may experience problems with their vision or show signs of neurological impairment affecting their ability to move or coordinate their movements.[12]
Sadly, HHV-6 encephalitis can be fatal in both adults and children if not recognized and treated promptly. The severity of symptoms often reflects how compromised the immune system has become and how extensively the virus has invaded brain tissue. Some patients may slip into a coma, require mechanical ventilation to breathe, or develop paralysis. Recovery can be prolonged and may require intensive rehabilitation to regain lost functions such as walking or bladder control.[1]
Prevention
Currently, no vaccine exists for HHV-6 infection, and none is in development at this time. This means prevention strategies focus primarily on careful monitoring and early detection rather than on preventing initial infection, which is essentially universal in early childhood.[7]
For high-risk patients, particularly those undergoing stem cell or solid organ transplantation, prevention strategies have centered on attempting to identify early reactivation before symptoms of encephalitis develop. However, these pre-emptive strategies using antiviral medications have proven challenging to implement successfully. The dynamics of HHV-6 DNA levels in blood and how they correlate with the risk of developing encephalitis remain poorly understood. Additionally, the antiviral drugs used to treat HHV-6—such as foscarnet and ganciclovir—carry significant toxicities that can be unacceptably high in the transplant setting. Foscarnet can cause serious kidney damage, while ganciclovir can suppress bone marrow function and reduce blood cell counts.[7]
Because of these challenges and the lack of strong evidence demonstrating that prophylactic treatment prevents encephalitis, routine prophylaxis for HHV-6 infection in stem cell transplant recipients is not recommended by current guidelines. Instead, the emphasis falls on maintaining a high index of suspicion, monitoring patients closely during the highest-risk periods, and initiating treatment rapidly when symptoms suggest encephalitis may be developing.[7]
For the general population and for immunocompetent individuals, prevention efforts focus more broadly on maintaining overall immune health through good nutrition, adequate sleep, stress management, and treatment of any underlying conditions that might compromise immunity. For transplant recipients specifically, adhering closely to prescribed immunosuppression protocols helps balance the need to prevent organ rejection while not suppressing immunity more than necessary.[2]
Pathophysiology
The pathophysiology of HHV-6 encephalitis—meaning the specific changes that occur in the body during this disease—involves complex interactions between the virus and the nervous system. HHV-6 is classified as a beta-herpesvirus, a group that includes cytomegalovirus and other related viruses. The virus consists of double-stranded DNA wrapped in a protein coat, and like other herpesviruses, it has evolved sophisticated mechanisms to hide from the immune system and persist in the body for life.[2]
After primary infection in childhood, HHV-6 establishes latency primarily in mononuclear cells—a category that includes lymphocytes and monocytes. The virus also persists at low levels in various tissues throughout the body. During this latent phase, the viral genetic material remains in cells but does not actively produce new virus particles. The immune system keeps this dormant infection in check through constant surveillance.[3]
When immune surveillance weakens significantly, the virus can reactivate and begin replicating again. HHV-6 demonstrates what scientists call neurotropism, meaning it has a natural affinity for nervous system tissue. The virus can infect various cell types in the brain including neurons (nerve cells), glial cells (support cells), and cells lining blood vessels. Once reactivation occurs, the virus begins actively producing new virus particles that can spread to adjacent cells and through the cerebrospinal fluid that bathes the brain and spinal cord.[3]
The inflammation that defines encephalitis results from both direct viral damage to brain cells and the immune system’s response to the infection. As the virus replicates in brain tissue, it damages or kills infected cells. The immune system, even in its weakened state, attempts to fight back by sending inflammatory cells into the brain tissue. This inflammatory response, while intended to help, actually contributes to brain swelling and tissue damage.[1]
Imaging studies using MRI scans in patients with HHV-6 encephalitis often reveal characteristic patterns of inflammation, particularly affecting the temporal lobes and hippocampus—brain structures critical for memory formation and emotional processing. Over time, even with treatment, many patients develop what doctors call hippocampal atrophy, meaning the hippocampus shrinks and loses tissue volume. This physical damage to brain structure helps explain why many survivors experience persistent memory problems and other cognitive difficulties long after the acute infection has been treated.[1]
The virus also affects other body systems beyond the brain. It can replicate in the salivary glands, which helps explain how the virus spreads through saliva in healthy children. In immunocompromised patients, HHV-6 reactivation has been associated with various other complications including liver inflammation (hepatitis), pneumonitis (lung inflammation), bone marrow suppression affecting blood cell production, and gastrointestinal problems such as colitis. Some evidence also suggests the virus may contribute to rejection of transplanted organs, though the mechanisms remain under investigation.[12]
